(Q37766754)

22 August 2017

1 reference

title

Prostate cancer prevention: concepts and clinical recommendations (English)

1 reference

22 August 2017

1 reference

J L Silberstein

1

1 reference

22 August 2017

J K Parsons

series ordinal

2

1 reference

22 August 2017

publication date

22 June 2010

1 reference

Prostate Cancer and Prostatic Diseases

22 August 2017

published in

1 reference

22 August 2017

volume

13

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

300-306

1 reference

22 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

The economic costs of early stage prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Statins and prostate cancer prevention: where we are now, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Diet and prostate cancer risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Estrogen receptor expression in prostate cancer and premalignant prostatic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Clinical interpretation of prostate biopsy reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Pathologic stage migration has slowed in the late PSA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

The cost of prostate cancer chemoprevention: a decision analysis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Inhibition by vitamin C of DNA adduct formation and arylamine N-acetyltransferase activity in human bladder tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

EAU guidelines on prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Treatment with finasteride following radical prostatectomy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

Fruit and vegetable intakes and prostate cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2010.18

31 March 2020

Identifiers

DOI

10.1038/PCAN.2010.18

1 reference

22 August 2017

1 reference